{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.4","value":"90.5"},{"groupId":"OG001","spread":"13.5","value":"86.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 49-72 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better.","dispersionType":"Standard Deviation","groups":[{"description":"Includes eligible patients 3-7 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the LDCSI arms (Treatment Arms I or II) and with a post-treatment TSH value.","id":"OG000","title":"Low-dose Craniospinal Radiation (LDSCI)"},{"description":"Includes eligible patients 3-7 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the SDCSI arms (Treatment Arms III or IV) and with a post-treatment TSH value.","id":"OG001","title":"Standard-dose Craniospinal Radiation (SDCSI)"}],"paramType":"MEAN","populationDescription":"Eligible and evaluable patients are reported.","reportingStatus":"POSTED","timeFrame":"49 - 72 months post diagnosis","title":"Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}